A teal muscle cross-section with rounded fascicles beside a separate peptide ribbon.

Our evidence assessments are specific to an outcome, population, and formulation.

Read our grading method

Tesamorelin

Explore Tesamorelin study records from the local packet, with missing evidence clearly marked.

Research topics
Primary investigators

Recorded source check: 3 October 2026

Review and updates

Overview

The studies linked here examine tesamorelin in specific clinical populations, including diabetes and HIV-associated muscle imaging. The study excerpts retain the study population, route and endpoint.[1][2] These findings belong to the population and intervention in each paper. They do not establish outcomes for the tesamorelin combinations listed on this site.[1][2] The sections below distinguish measured findings from broader benefit claims and identify the information needed to interpret formulation, timing, and safety. A result remains attached to the population and intervention in which it was observed.

Benefits

Research records for Tesamorelin are linked in the study collections below, but their presence is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.

Safety

This Tesamorelin guide does not yet provide a complete clinical safety assessment for a specific formulation and use. Such an assessment would need the exposure, route, participant characteristics, adverse events, and duration of follow-up from the relevant primary studies. Missing safety information cannot be interpreted as an absence of risk, and a reported event needs context before causation is assigned. Findings from one setting should remain separate from claims about another product, population, or combination.

Contraindications

The evidence summarized on this Tesamorelin page is not sufficient to construct a complete contraindication list for clinical use. A study’s inclusion and exclusion criteria describe its selected participants, but they do not determine suitability for everyone outside that study. Interpreting a potential contraindication requires the exact product, intended use, health condition, and supporting evidence. This section therefore leaves unanswered suitability questions explicit instead of turning unstudied circumstances into either permission or a categorical clinical rule.

Interactions

This guide does not establish an interaction profile for Tesamorelin with other peptides, medicines, or supplements. To evaluate a particular combination, the relevant evidence would need to identify the coadministered substances, formulation, route, and measured effects. Results for ingredients studied separately cannot determine whether combining them changes benefit, exposure, or harm. Related stack pages distinguish those ingredient findings from direct combination evidence and keep any unresolved interaction questions visible.

Forms & dosing

A validated dosing recommendation for Tesamorelin cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.

Results & stopping

This Tesamorelin guide does not establish a general time to benefit or what happens after treatment stops. Those questions require a defined outcome, repeated measurements, and follow-up that extends beyond the intervention when persistence is being assessed. A pharmacological response during exposure would answer a different question from a sustained improvement in symptoms or function. Any future timeline should therefore state exactly what changed, when it was measured, and whether the study actually observed participants after discontinuation.

Product quality

The studies attached to a topic do not, by themselves, validate the quality of a commercial Tesamorelin product. Evaluating a particular preparation requires information about its identity, composition, batch, and intended route, with testing appropriate to the claim being made. A supplier’s label cannot establish that the contents match a research intervention. This guide keeps product characterization separate from clinical effectiveness and does not endorse a vendor or finished product on the basis of an ingredient study.

Status

This page does not provide a verified, product-specific regulatory determination for Tesamorelin. Approval, research use, and availability need to be distinguished for the exact preparation, indication, and jurisdiction being considered. A publication establishes that an experiment was reported; it does not by itself establish authorization to market a product. Regulatory conclusions should be added only with a dated primary agency source, while research findings remain tied to the intervention actually investigated.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Selected findings and their main limitations. Open an outcome or source count for the complete assessment. Counts refer to cited documents, not necessarily independent studies.
Outcome, finding and study designEvidence certaintySources

No outcome assessment is available for this guide yet. Source records below have not been synthesized into an assessment of benefit or safety.

Inspect the available research

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

PDF recordEffect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial
PDF recordDelineating tesamorelin response pathways in HIV‑associated NAFLD using a targeted proteomic and transcriptomic approach
PDF recordEffects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
PDF recordSafety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial
Review status · Pending
Selected passages

The objective of this study was to determine whether tesamorelin, a stabilized growth hormonereleasing hormone analogue, would alter insulin sensitivity or control of diabetes.

Safety_and_metabolic_effects_of_tesamorelin_a_growth_hormone_releasing_f_28617838_PMC5472315.pdf · PDF page 1

Statistical analyses The primary endpoint of the study was the relative insulin response over the 12-week treatment period.

Safety_and_metabolic_effects_of_tesamorelin_a_growth_hormone_releasing_f_28617838_PMC5472315.pdf · PDF page 4

After screening and a 14-day lead-in period to establish and characterize daily dietary patterns and blood measurements, patients diabetes were randomly assigned to receive either placebo, tesamorelin 1 mg, or tesamorelin 2 mg, administered by subcutaneous injection for 12 weeks (Fig 1).

Safety_and_metabolic_effects_of_tesamorelin_a_growth_hormone_releasing_f_28617838_PMC5472315.pdf · PDF page 2

There was a borderline effect of time on fasting glucose (p = 0.06), with glucose values higher in the tesamorelin 2 mg group at Weeks 4 and 8 compared to values in the other groups.

Safety_and_metabolic_effects_of_tesamorelin_a_growth_hormone_releasing_f_28617838_PMC5472315.pdf · PDF page 8

DOI: 10.1371/journal.pone.0179538

PDF recordTHE GROWTH HORMONE RELEASING HORMONE ANALOGUE, TESAMORELIN, DECREASES MUSCLE FAT AND INCREASES MUSCLE AREA IN ADULTS WITH HIV
Review status · Pending
Selected passages

The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality, as measured by changes in computed tomography (CT)based trunk muscle density, a biopsy-correlated measurement of skeletal muscle fat (26), and trunk muscle area.

The_Growth_Hormone_Releasing_Hormone_Analogue_Tesamorelin_Decreases_Musc_31237318_PMC6766405.pdf · PDF page 2

DOI: 10.14283/jfa.2018.45

PDF recordThe effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment
PDF recordTesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol
PDF recordPredictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat
PDF recordCombined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model
PDF recordTesamorelin: A hope for ART- induced lipodystrophy
PDF recordCarpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study
PDF record1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV
PDF recordP-433. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis
PDF recordP-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants
PDF recordGrowth Hormone Releasing Hormone Reduces Plasma Markers of Immune Activation and Hepatic Immune Pathways in Nonalcoholic Fatty Liver Disease

FAQs

What can this guide currently establish about Tesamorelin?
Quick answer:

Research records for Tesamorelin are linked in the study collections below, but their presence is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.

Do reported study amounts establish a dosing recommendation?
Quick answer:

A validated dosing recommendation for Tesamorelin cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for Tesamorelin.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

2 sources
  1. Safety_and_metabolic_effects_of_tesamorelin_a_growth_hormone_releasing_f_28617838_PMC5472315.pdf (Accessed 2026-10-04)Primary research · See study record for population and routeReview status · PendingSave study
  2. The_Growth_Hormone_Releasing_Hormone_Analogue_Tesamorelin_Decreases_Musc_31237318_PMC6766405.pdf (Accessed 2026-10-04)Primary research · See study record for population and routeReview status · PendingSave study